An enriched population of primate induced pluripotent cells which are substantially genetically identical to a post-natal individual, wherein the population is produced according to a method comprising the steps of: introducing a plurality of non-viral episomal vectors encoding one or more potency-determining factors into the primate somatic cells under conditions sufficient to express the potency-determining factors, thereby reprogramming the somatic cells to produce the primate pluripotent cells; wherein at least some of the primate induced pluripotent cells in the enriched population comprise one or more copies of the plurality of non-viral episomal vectors; wherein the plurality of non-viral episomal vectors is selected from the group consisting of: (a) a first vector comprising, in order, a first promoter, OCT4, IRES2, SOX2, a second promoter, SV40 T antigen, IRES2, and KLF4, a second vector comprising, in order, a third promoter, OCT4, IRES2, SOX2, a fourth promoter, NANOG, IRES2, and KLF4, and a third vector comprising, in order, a fifth promoter, c-Myc, IRES 2, and LN28, wherein the promoters need not be identical; (b) a first vector comprising, in order, a first promoter, OCT4, IRES2, SOX2, a second promoter, KLF4, IRES2, c-Myc, a third promoter, NANOG, IRES2, and LN28, a second vector comprising, in order, a fourth promoter, OCT4, IRES2, SOX2, a fifth promoter, SV40 T antigen, IRES2, and KLF4, wherein the promoters need not be identical; and (c) a first vector comprising, in order, a first promoter, OCT4, IRES2, SOX2, a second promoter, NANOG, IRES2, and LN28, a second vector comprising, in order, a third promoter, OCT4, IRES2, SOX2, a fourth promoter, SV40 T antigen, IRES2, and KLF4, and a third vector comprising, in order, a fifth promoter, OCT4, IRES2, SOX2, a sixth promoter, c-Myc, IRES 2, and KLF4, wherein the promoters need not be identical. introducing a plurality of non-viral episomal vectors encoding one or more potency-determining factors into the primate somatic cells under conditions sufficient to express the potency-determining factors, thereby reprogramming the somatic cells to produce the primate pluripotent cells; wherein at least some of the primate induced pluripotent cells in the enriched population comprise one or more copies of the plurality of non-viral episomal vectors; wherein the plurality of non-viral episomal vectors is selected from the group consisting of: (a) a first vector comprising, in order, a first promoter, OCT4, IRES2, SOX2, a second promoter, SV40 T antigen, IRES2, and KLF4, a second vector comprising, in order, a third promoter, OCT4, IRES2, SOX2, a fourth promoter, NANOG, IRES2, and KLF4, and a third vector comprising, in order, a fifth promoter, c-Myc, IRES 2, and LN28, wherein the promoters need not be identical; (b) a first vector comprising, in order, a first promoter, OCT4, IRES2, SOX2, a second promoter, KLF4, IRES2, c-Myc, a third promoter, NANOG, IRES2, and LN28, a second vector comprising, in order, a fourth promoter, OCT4, IRES2, SOX2, a fifth promoter, SV40 T antigen, IRES2, and KLF4, wherein the promoters need not be identical; and (c) a first vector comprising, in order, a first promoter, OCT4, IRES2, SOX2, a second promoter, NANOG, IRES2, and LN28, a second vector comprising, in order, a third promoter, OCT4, IRES2, SOX2, a fourth promoter, SV40 T antigen, IRES2, and KLF4, and a third vector comprising, in order, a fifth promoter, OCT4, IRES2, SOX2, a sixth promoter, c-Myc, IRES 2, and KLF4, wherein the promoters need not be identical. (a) a first vector comprising, in order, a first promoter, OCT4, IRES2, SOX2, a second promoter, SV40 T antigen, IRES2, and KLF4, a second vector comprising, in order, a third promoter, OCT4, IRES2, SOX2, a fourth promoter, NANOG, IRES2, and KLF4, and a third vector comprising, in order, a fifth promoter, c-Myc, IRES 2, and LN28, wherein the promoters need not be identical; (b) a first vector comprising, in order, a first promoter, OCT4, IRES2, SOX2, a second promoter, KLF4, IRES2, c-Myc, a third promoter, NANOG, IRES2, and LN28, a second vector comprising, in order, a fourth promoter, OCT4, IRES2, SOX2, a fifth promoter, SV40 T antigen, IRES2, and KLF4, wherein the promoters need not be identical; and (c) a first vector comprising, in order, a first promoter, OCT4, IRES2, SOX2, a second promoter, NANOG, IRES2, and LN28, a second vector comprising, in order, a third promoter, OCT4, IRES2, SOX2, a fourth promoter, SV40 T antigen, IRES2, and KLF4, and a third vector comprising, in order, a fifth promoter, OCT4, IRES2, SOX2, a sixth promoter, c-Myc, IRES 2, and KLF4, wherein the promoters need not be identical.